quinazolines has been researched along with 3,3'-diindolylmethane in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH; Schaffert, JM | 1 |
2 other study(ies) available for quinazolines and 3,3'-diindolylmethane
| Article | Year |
|---|---|
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence; Humans; Indoles; Mice; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |